The Incidence and Significance of Anti-Natalizumab Antibodies: Results from AFFIRM and SENTINEL
Neurol 69:1391-1403,1396, Calabresi,P.A.,et al, 2007
Guidelines For Using Proton MR Spectroscopy in Multicenter Clinical MS Studies
Neurol 69:1942-1952, De Stefano,N.,et al, 2007
Long-Term Prognosis in Children With Neonatal Seizures: A Population-Based Study
Neurol 69:1816-1822, Ronen,G.M.,et al, 2007
Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab
Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007
Natalizumab (Tysabri) Treatment for Relapsing Multiple Sclerosis
The Neurologist 13:182-187, Johnson,K.P., 2007
Electromyographic Biofeedback for the Recovery of Motor Function After Stroke
Stroke 38:1999-2000, Woodford,H.J. &Price,C., 2007
Natural History of Multiple Sclerosis with Childhood Onset
NEJM 356:2603-2613, Renoux,C.,et al, 2007
Natalizumab for Multiple Sclerosis
NEJM 356:2622-2629, Ransohoff,R.M., 2007
Neuropsychiatric Syndromes Associated With Multiple Sclerosis
J Neurol 254:II/73-II/76, Feinstein,A., 2007
Balos Concentric Sclerosis Presenting as a Stroke-Like Syndrome
Nat Clin Pract Neurol 3:349-354, Mowry,E.M.,et al, 2007
Multiple Sclerosis After Infectious Mononucleosis
Arch Neurol 64:72-75, Nielsen,T.R.,et al, 2007
Clinicopath Conf., Paraneoplastic Cerebellar Degeneration Due to Anti-Yo Antibodies From Breast Cancer
NEJM 356:612-620, Case 4-2007, 2007
Diagnosis and Treatment of Neuromyelitis Optica
The Neurologist 13:2-11, Wingerchuk,D.M., 2007
Longitudinal Follow-Up of "Benign" Multiple Sclerosis at 20 Years
Neurol 68:496-500,480, Sayao,A-L.,et al, 2007
Gray Matter Involvement in Multiple Sclerosis
Neurol 68:634-642, Pirko,I.,et al, 2007
Sexual Function in Men and Women With Neurological Disorders
Lancet 369:512-525, Rees,P.M.,et al, 2007
Neurodevelopment and Cognition in Children After Enterovirus 71 Infection
NEJM 356:1226-1234, Chang,L.-Y.,et al, 2007
Randomized, Double-Blind, Dose-Comparison Study of Glatiramer Acetate in Relapsing-Remitting MS
Neurol 68:939-944, Cohen,J.A.,et a, 2007
Reactivation of JC Virus and Development of PML in Patients With Multiple Sclerosis
Neurol 68:985-990, Khalili,K.,et al, 2007
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007
NMO-IgG in the Diagnosis of Neuromyelitis Optica
Neurol 68:1076-1077, Jarius,S.,et al, 2007
Natalizumab Reduces Visual Loss in Patients with Relapsing Multiple Sclerosis
Neurol 68:1299-1302, Balcer,L.J.,et al, 2007
Neurologic Complications of Gastric Bypass Surgery for Morbid Obesity
Neurol 68:1843-1850, Juhasz-Pocsine,K.,et al, 2007
Orthostatic Myoclonus: A Contributor to Gait Decline in Selected Elderly
Neurol 68:1826-1830, Glass,G.A.,et al, 2007
Mitoxantrone for Multiple Sclerosis Causing Acute Lymphoblastic Leukemia
Neurol 68:1630-1631, Cartwright,M.S.,et al, 2007
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
MRI Outcomes in a Placebo-Controlled Trial of Natalizumab in Relapsing MS
Neurol 68:1390-1401, Miller,D.H.,et al, 2007
Dementia and White-Matter Demyelination in Young Patient With Neurosyphilis
Lancet:368:2258, Brinar,V.V. &Habek,M., 2006
High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis
Arch Neurol 63:1388-1393, Gladstone,D.E.,et al, 2006
Neuromyelitis Optica IgG Status in Acute Partial Transverse Myelitis
Arch Neurol 63:1398-1400, Scott,T.F.,et al, 2006
Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis
JAMA 296:2832-2838, Munger,K.L.,et al, 2006
Infusion-Related Hypersensitivity Reactions During Natalizumab Treatment
Neurol 67:1717-1718, Phillips,J.T.,et al, 2006
Multiple Sclerosis with and without CSF Bands:Clinically Indistinguishable but Immunogenetically Distinct
Neurol 67:1062-1064, Imrell,K.,et al, 2006
In Vivo Detection of Cortical Plaques by MR Imaging in Patients with Multiple Sclerosis
AJNR 27:2161-2167, Bagnato,F.,et al, 2006
Pathologic Laughing and Intractable Hiccups Can Occur Early in Multiple Sclerosis
Neurol 67:1684-1686, de Seze,J.,et al, 2006
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
NEJM 355:1124-1140, Kappos,L.,et al, 2006
Significance of T2 Lesions in Multiple Sclerosis: A 13-Year Longitudinal Study
Ann Neurol 60:236-242, Rudick,R.A.,et al, 2006
Interferon beta-1a Treatment in Childhood and Juvenile-Onset Multiple Sclerosis
Neurol 67:511-513, Tenembaum,S.N. &Segura,M.J., 2006
Obsessive-Compulsive Disorder
BMJ 333:424-429, Heyman,I.,et al, 2006
Treatment of Low Back Pain by Acupressure and Physical Therapy: Randomised Controlled Trial
BMJ 332:696-698,680, Hsieh,L.L.-C.,et al, 2006
Magnetic Resonance Imaging as a Surrogate Outcome Measure of Disability in Multiple Sclerosis: Have We Been Overly Harsh in Our Assessment?
Ann Neurol 59:597-605, Goodin,D.S., 2006
Not All Patients With Atrial Fibrillation-Associated Ischemic Stroke Can Be Started on Anticoagulant Therapy
Stroke 37:1217-1220, Somerfield,J.,et al, 2006
Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006
MRI T2 Lesion Burden in Multiple Sclerosis. A Plateauing Relationship with Clinical Disability.
Neurol 66:1384-1389, Li,D.K.B.,et al, 2006
Multiple Sclerosis: New Insights and Trends
AJNR 27:954-957, Inglese,M., 2006
Past Adult Lead Exposure is Linked to Neurodegeneration Measured by Brain MRI
Neurol 66:1476-1484,1464, Stewart,W.F.,et al, 2006
Revised Diagnostic Criteria for Neuromyelitis Optica
Neurol 66:1485-1489, Wingerchuk,D.M.,et al, 2006
Tetanus Vaccination and Risk of Multiple Sclerosis: A Systematic Review
Neurol 67:212-215, Hernn,M.A.,et al, 2006
The Clinical Features, MRI Findings, and Outcome of Optic Neuritis in Children
Neurol 67:258-262, Wilejto,M.,et al, 2006
Emerging Monoclonal Antibody Therapies for Multiple Sclerosis
Neurologist 12:171-178, Cree,B., 2006